Edwards Lifesciences Corporation (EW)Healthcare | Medical Devices | Irvine, United States | NYSE
91.79 USD
-0.42
(-0.455%) ⇩
(July 13, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | July 11, 2026, 5:09 a.m. EDT
Edwards Lifesciences presents a compelling long-term investment case driven by robust fundamentals, yet the short-term outlook is clouded by recent insider selling and a single year of earnings contraction. The company maintains a fortress balance sheet with over three billion dollars in cash against minimal debt, and revenue growth remains healthy at sixteen percent annually. While the stock has underperformed over the last fiscal year with a fifteen percent decline, this isolated dip does not constitute a structural deterioration given the nine-year cumulative gain of one hundred twenty-four percent. The recent price action is encouraging, trading above both the fifty-day and two-hundred-day moving averages, suggesting institutional accumulation. However, the lack of a dividend yield and the recent executive stock sales introduce friction for immediate capital appreciation. Investors should view this as a core holding for growth rather than a speculative trade, waiting for the dust to settle on the recent earnings miss before adding significant weight. |
| Model | MAE |
|---|---|
| MSTL_70 ✓ | 0.058641 |
| MSTL_70_115 | 0.067067 |
| AutoARIMA | 0.088032 |
| AutoETS | 0.088032 |
| MSTL | 0.088094 |
| AutoTheta | 0.093092 |
| MSTL_115 | 0.094295 |
Forecast horizon: 60 days | Selected: MSTL_70
| Forecast Reliability | |
|---|---|
| Score | 43% |
| H-stat | 8.32 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.254 |
| Excess Kurtosis | -0.20 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 6.806 |
| Revenue per Share | 10.814 |
| Market Cap | 52,852,682,752 |
| Trailing P/E | 49.62 |
| Forward P/E | 27.26 |
| Beta | 0.86 |
| Profit Margins | 17.39% |
| Website | https://www.edwards.com |
As of July 11, 2026, 5:09 a.m. EDT: Speculators are positioning for a range-bound recovery with a bullish bias toward the 100 strike level for later expirations, while heavy put open interest at the 70 to 80 range suggests a defensive floor is being established. Implied volatility is significantly elevated on deep out-of-the-money puts for 2027, indicating fear of a sharp downside event, whereas call volume remains concentrated near the money and at the 100 strike.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.17795098 |
| Address1 | One Edwards Way |
| All Time High | 131.73 |
| All Time Low | 1.0 |
| Ask | 94.44 |
| Ask Size | 400 |
| Audit Risk | 4 |
| Average Analyst Rating | 1.7 - Buy |
| Average Daily Volume10 Day | 5,018,090 |
| Average Daily Volume3 Month | 5,150,991 |
| Average Volume | 5,150,991 |
| Average Volume10Days | 5,018,090 |
| Beta | 0.855 |
| Bid | 0.0 |
| Bid Size | 300 |
| Board Risk | 2 |
| Book Value | 17.899 |
| City | Irvine |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 4 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 91.79 |
| Current Ratio | 4.421 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 93.09 |
| Day Low | 91.57 |
| Debt To Equity | 6.806 |
| Display Name | Edwards Lifesciences |
| Earnings Call Timestamp End | 1,784,836,800 |
| Earnings Call Timestamp Start | 1,784,836,800 |
| Earnings Growth | 0.082 |
| Earnings Quarterly Growth | 0.063 |
| Earnings Timestamp | 1,784,836,800 |
| Earnings Timestamp End | 1,784,836,800 |
| Earnings Timestamp Start | 1,784,836,800 |
| Ebitda | 1,903,600,000 |
| Ebitda Margins | 0.30199 |
| Enterprise To Ebitda | 26.205 |
| Enterprise To Revenue | 7.914 |
| Enterprise Value | 49,884,082,176 |
| Eps Current Year | 3.00742 |
| Eps Forward | 3.36782 |
| Eps Trailing Twelve Months | 1.85 |
| Esg Populated | 0 |
| Exchange | NYQ |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 86.3478 |
| Fifty Day Average Change | 5.4421997 |
| Fifty Day Average Change Percent | 0.0630265 |
| Fifty Two Week Change Percent | 17.795097 |
| Fifty Two Week High | 96.29 |
| Fifty Two Week High Change | -4.5 |
| Fifty Two Week High Change Percent | -0.046733823 |
| Fifty Two Week Low | 72.3 |
| Fifty Two Week Low Change | 19.489998 |
| Fifty Two Week Low Change Percent | 0.2695712 |
| Fifty Two Week Range | 72.3 - 96.29 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 954,167,400,000 |
| Float Shares | 573,986,230 |
| Forward Eps | 3.36782 |
| Forward P E | 27.25502 |
| Free Cashflow | 902,137,472 |
| Full Exchange Name | NYSE |
| Full Time Employees | 16,000 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | 0.77866 |
| Gross Profits | 4,908,299,776 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.00184 |
| Held Percent Institutions | 0.94176 |
| Implied Shares Outstanding | 575,800,000 |
| Industry | Medical Devices |
| Industry Disp | Medical Devices |
| Industry Key | medical-devices |
| Ir Website | http://ir.edwards.com/ |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,590,969,600 |
| Last Split Factor | 3:1 |
| Long Business Summary | Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL and EVOQUE brands. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS brand name; INSPIRIS RESILIA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valve conduit for complex combined procedures; and MITRIS RESILIA valve. It distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California. |
| Long Name | Edwards Lifesciences Corporation |
| Market | us_market |
| Market Cap | 52,852,682,752 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_411220 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | 1,075,600,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 52,852,682,000 |
| Number Of Analyst Opinions | 26 |
| Open | 92.275 |
| Operating Cashflow | 1,358,599,936 |
| Operating Margins | 0.31219998 |
| Overall Risk | 2 |
| Payout Ratio | 0.0 |
| Peg Ratio | 2.21 |
| Phone | 949 250 2500 |
| Pre Market Change | -1.4759979 |
| Pre Market Change Percent | -1.6074907 |
| Pre Market Price | 90.344 |
| Pre Market Time | 1,784,027,178 |
| Previous Close | 92.21 |
| Price Eps Current Year | 30.521177 |
| Price Hint | 2 |
| Price To Book | 5.1282196 |
| Price To Sales Trailing12 Months | 8.384657 |
| Profit Margins | 0.1739 |
| Quick Ratio | 3.296 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 1.68966 |
| Region | US |
| Regular Market Change | -0.419998 |
| Regular Market Change Percent | -0.45548 |
| Regular Market Day High | 93.09 |
| Regular Market Day Low | 91.57 |
| Regular Market Day Range | 91.57 - 93.09 |
| Regular Market Open | 92.275 |
| Regular Market Previous Close | 92.21 |
| Regular Market Price | 91.79 |
| Regular Market Time | 1,783,972,802 |
| Regular Market Volume | 2,210,935 |
| Return On Assets | 0.08269 |
| Return On Equity | 0.1046 |
| Revenue Growth | 0.167 |
| Revenue Per Share | 10.814 |
| Sand P52 Week Change | 0.20365608 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 4 |
| Shares Outstanding | 575,800,000 |
| Shares Percent Shares Out | 0.0199 |
| Shares Short | 11,466,764 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 12,163,159 |
| Short Name | Edwards Lifesciences Corporatio |
| Short Percent Of Float | 0.0227 |
| Short Ratio | 2.22 |
| Source Interval | 15 |
| State | CA |
| Symbol | EW |
| Target High Price | 110.0 |
| Target Low Price | 84.0 |
| Target Mean Price | 98.57692 |
| Target Median Price | 100.0 |
| Total Cash | 3,671,500,032 |
| Total Cash Per Share | 6.376 |
| Total Debt | 702,899,968 |
| Total Revenue | 6,303,499,776 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 1.85 |
| Trailing P E | 49.616215 |
| Trailing Peg Ratio | 2.2055 |
| Triggerable | 1 |
| Two Hundred Day Average | 82.92185 |
| Two Hundred Day Average Change | 8.868149 |
| Two Hundred Day Average Change Percent | 0.10694586 |
| Type Disp | Equity |
| Volume | 2,210,935 |
| Website | https://www.edwards.com |
| Zip | 92,614 |